Evidence map›Paper›PMID 25903466›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015

Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma.

Lin Chen, Feihu Chu, Yali Cao, Jianguo Shao, Feng Wang

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Role of Extracellular Vesicles in Liver Diseases.Life (Basel, Switzerland) · 2023
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Exosomal microRNAs in hepatocellular carcinoma.Cancer cell international · 2021
    Review
  17. mir-182-5p Regulates Cell Growth of Liver Cancer via Targeting RCAN1.Gastroenterology research and practice · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lin ChenDepartment of Gastroenterology and Clinical Laboratory, The Third People's Hospital of Nantong City, Jiangsu, 226006, China.
Feihu ChuDepartment of General Surgery, The Sixth People's Hospital of Nantong City, Jiangsu, 226011, China.
Yali CaoDepartment of Gastroenterology and Clinical Laboratory, The Third People's Hospital of Nantong City, Jiangsu, 226006, China.
Jianguo ShaoDepartment of Gastroenterology and Clinical Laboratory, The Third People's Hospital of Nantong City, Jiangsu, 226006, China. xiaobei227@sina.com.
Feng WangDepartment of Clinical Laboratory Center, Affiliated Hospital of Nantong University, Jiangsu, 226001, China. richardwangf@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have identified a number of microRNAs (miRNAs) that were aberrantly expressed in hepatocellular carcinoma (HCC) tissues. Nevertheless, their diagnostic and prognostic value in serum has not been fully evaluated. Herein, the levels of five serum miRNAs, namely, miR-182, miR-331-3p, miR-197, miR-492, and miR-581, were detected in 103 HCC patients, 95 benign liver diseases, and 40 healthy controls using real-time PCR technique. The results showed that, compared with benign liver diseases and healthy controls, the levels of serum miR-182 and miR-331-3p were significantly increased in HCC patients, both P < 0.001. Area under the receiver-operating characteristic (ROC) curves for serum miR-182 and miR-331-3p were 0.911 (95 % CI, 0.863-0.947) and 0.890 (95 % CI, 0.838-0.930), the sensitivity were 78.6 and 79.61 %, and the specificity were 91.58 and 86.32 %, respectively. Moreover, the combination of serum miR-182, miR-331-3p, and alpha-fetoprotein (AFP) can markedly increase the differential diagnostic value of benign and malignant liver diseases, especially better than serum AFP alone, P < 0.05. Serum miR-182 was positively correlated with serum AFP (P = 0.001), tumor size (P = 0.013), and TNM classification of malignant tumors (TNM) stage (P = 0.003); however, only TNM stage was demonstrated a significant correlation with serum miR-331-3p (P = 0.006). In addition, Kaplan-Meier survival curve, together with univariate and multivariate Cox proportional hazard analyses, further disclosed that serum miR-182 and miR-331-3p were associated with postoperative survival of HCC patients, and both of them were regarded to be independent prognostic factors for patients with HCC. Taken together, our present study indicates that serum miR-182 and miR-331-3p, upregulated in HCC, can provide positive diagnostic and prognostic values for HCC.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, HepatocellularCase-Control StudiesFemaleFollow-Up StudiesHumansLiverLiver NeoplasmsMaleMicroRNAsMiddle AgedMultivariate AnalysisNeoplasm StagingBiomarkers, TumorMicroRNAsMirn182 microRNA, humanMIRN331 microRNA, humanAlpha-fetoproteinDiagnosisHepatocellular carcinomaMicroRNA-182MicroRNA-331-3pPrognosis

Identifiers

PMID25903466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.